BioWorld

May 12, 2004

View Archived Issues

With SPA Agreement, Xenova Plans Two TransMID Phase IIIs

Xenova Group plc immediately expects to commence the first of two planned Phase III trials for TransMID, a candidate for brain cancer. (BioWorld Today) Read More

Illumina Files $65M Shelf, Raises $31M In Direct Sale

Read More

Mutation, Rash Clues May Sharpen Focus For EGFR Cancer Therapies

Read More

Nearing Human Trials, Acuity's Approach Attracting Investors

Read More

Other News To Note

Read More